ECL letter regarding the importance of collaboration in cancer research after Brexit
31 January 2020, Brussels
Dear Mr Kiik,
As the negotiating mandate for future relationship talks with the United Kingdom is finalised, I am
writing on behalf of the Association of European Cancer Leagues (ECL) regarding the importance of
protecting the interests of cancer patients and medical research.
ECL represents 29 national cancer leagues across 24 countries with a joint vision of a Europe free of
cancers. We cover the full patient pathway, from prevention, early diagnosis, treatment and patient
support. We bring together some of Europe’s largest charitable research funders, with ECL members
committing over €700 million to cancer research in 2018/19. With more than 3.7 million new cancer
cases and 1.9 million deaths each year, Europe accounts for 23.4% of cancer cases and 20.3% of cancer
deaths globally. This is a Europe-wide challenge which requires a coordinated response.
It is vital that this shared vision and ambition is not negatively impacted by the UK’s exit from the
EU, nor by the terms of the future relationship. UK-EU collaboration benefits people affected by
cancer across Europe and supports our world-leading research environment. As the Commission’s
mandate for negotiations is decided, we ask that it recognises the value of continued cooperation with
the UK on health and research.
In particular, we want to ensure that the future relationship protects:
• International Clinical Trials: Cross-border trials are vital for rare and paediatric cancers,
where single countries may not have sufficient participants to run trials. The UK has been a
significant contributor to such research and is currently involved in 28% of all EU trials, with
4,800 UK-EU trials between 2004 and 2016. With the Clinical Trial Regulation soon due to
come into force, we would like the UK to continue to play an active role in European clinical
research, including access to the Regulation’s infrastructure.
• Access to medicines and medical devices: The European Medicines Agency works to
improve the health of citizens across Europe, and the UK’s national regulator, the MHRA, has
been a productive partner. Between 2008 and 2016, the MHRA acted as Scientific Advice
Coordinator in over 20% of centralised EMA medicine approval procedures, and Rapporteur
or Co-Rapporteur in around 15% of centralised procedures. We believe negotiators should
build on commitments in the Political Declaration and consider mechanisms to allow the
MHRA to continue to participate in the EMA’s marketing authorisation processes. A close
www.cancer.eu | @cancerleagues
[email protected] | +32 2 256 2000
working relationship will also help protect the supply of vital medical devices to the EU – a
significant proportion of which originate in or come via the UK.
• Research collaboration: The UK and EU have deep links in medical research, built on shared
programmes, proximity and culture. The UK has been a major contributor, involved in 23 of
the 24 European Reference Networks (ERNs) which allow healthcare providers to share
knowledge and have driven progress across several rare cancers. Collaboration, like that
which comes through Research Framework Programmes, benefits both parties. Papers
involving UK and EU26 collaboration, for instance, are cited significantly more than those
with contributors in the UK or EU26 alone. Negotiators should understand the importance
and benefits of such collaboration for cancer patients and seek to ensure that the future UK-
EU relationship allows cooperation to flourish.
Clearly, there are a number of difficult questions to resolve around Brexit, but it is our sincere hope
that UK-EU cooperation on medical research need not be one. As the EU gives an unprecedented
focus to cancer research and control across the coming term, we believe these efforts will be
strengthened through collaboration with our British partners in a mutually beneficial relationship
that ultimately supports our joint vision of a Europe free of cancers.
Please do not hesitate to contact ECL for further information on the above, we would be pleased to
meet with you to discuss these issues in more detail.
Kind Regards,
__________________________ ________________________
Dr. Sakari Karjalainen Dr. Wendy Yared
President, ECL Director, ECL
www.cancer.eu | @cancerleagues
[email protected] | +32 2 256 2000
Saatja: Ginevra Papi <
[email protected]>
Saadetud: 31.01.2020 18:05
Adressaat: SM Info <
[email protected]>
Teema: ECL Open Letter - Importance of collaboration in cancer research after Brexit
Manused: image001.png; image002.png; image003.png; image004.png; image005.png;
image006.png; ECL letter_Cancer Research after Brexit 31012020.pdf
Dear Minister Kiik,
We are writing to you as the representative voice of cancer charities across the EU that support the
interests of European patients and the medical research community to urge you to ensure that access to
research funding and collaborative opportunities are prioritised in the post-Brexit negotiations which will
determine the UK’s future relationship with the EU.
Please find attached our open letter for your attention.
Kind regards,
Ginevra Papi
Communications Officer
Association of European Cancer Leagues (ECL)
Chaussée de Louvain / Leuvensesteenweg 479
Brussels | 1030 | Belgium
[email protected] |www.cancercode.eu